At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,507 enrolled
Drug / intervention
rimonabant (SR141716)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of Weight-Reducing Effect and Safety of SR141716 in Obese Patients With or Without Comorbidities (RIO-Europe)
In Brief
A Phase 3 clinical trial evaluating rimonabant (SR141716) for Obesity. Completed, enrolled 1,507 participants across 7 sites in 7 countries.
Detailed Summary
The primary objective was to assess the effect of SR141716 on weight loss and weight maintenance over a period of one year when prescribed with a hypocaloric diet in obese patients with or without comorbidities. The main secondary objectives were to assess the effect of SR141716 on lipid parameters (HDL-C, TG), glucose tolerance status, the rate of patients with metabolic syndrome, waist circumference, glycemic parameters.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesBelgium, Finland, France, Germany, Netherlands, Sweden, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2001
Primary CompletionJun 2004
First PostedOct 2006
TodayJul 2026
First PostedOct 11, 2006
Enrollment StartOct 1, 2001
Primary CompletionJun 1, 2004
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 19.7 years ago
Interventions
rimonabant (SR141716)drug